{"id":2622,"date":"2013-09-24T15:15:23","date_gmt":"2013-09-24T15:15:23","guid":{"rendered":"\/?p=2622"},"modified":"2013-09-24T15:15:30","modified_gmt":"2013-09-24T15:15:30","slug":"sologenix-inc-otcbbsngx-stuck-at-2","status":"publish","type":"post","link":"\/articles\/sologenix-inc-otcbbsngx-stuck-at-2\/","title":{"rendered":"Sologenix, Inc. (OTCBB:SNGX) Stuck at $2"},"content":{"rendered":"

Sologenix, Inc. (OTCBB:SNGX<\/a>), a promising pharmaceutical ticker, is having a bit of trouble jumping over the $2 mark. For three days, buying has outspaced selling, but still there are competing forces working on the stock. SNGX<\/a> added a bit more than 3% to stand exactly at $2, on volumes of above $298,000. After a good run, SNGX<\/a> is taking a breather, possibly expecting a correction. \"SNGX0923.png\" <\/p>\n

But underneath, SNGX<\/a> is promising amazing sales, capitalizing on one of the strongest market forces- fear and panic. SNGX<\/a> specialzies in producing agents against widespread threats, including radiation, biological weapons and toxins. If a nation decides to stockpile some of the promised solutions, this could mean fast and large revenues for SNGX<\/a>. \"NNVC0923.png\"<\/p>\n

It boggles the mind why SNGX<\/a> is not rising faster, except that the revenues are for now hypothetical. SNGX<\/a> was given a price target of $4.50, or up to $5. SNGX<\/a> has been as high as $7 before the downlisting in 2011. And it has not been promoted since the summer of 2011-all its gains in 2013 happened naturally on the development of treatments and vaccines that aim to solve global, unexpected threats.<\/p>\n

SNGX<\/a> expects eight total drug approvals, and the first one is to arrive this quarter. In case of good news, the climb could only continue. Still, SNGX<\/a> is not immune to the effect of sudden negative comments. The ticker may be somewhat protected by the $26 million contract, a significant sum for a low-float, small company.<\/p>\n

The new week will show if SNGX<\/a> lives up to expectations. Another well-liked ticker, NanoViricides, Inc. (OTCMKTS:NNVC<\/a>) was making the rounds with a robust, self-propelled climb. After the fallout around September 10th, NNVC<\/a> sprung back again, to post-split prices nearing $6, opening with a strong gain on Monday.<\/p>\n

Elite Pharmaceuticals, Inc. (OTCBB:ELTP<\/a>) is another strong contender, which is at around 15 cents, a peak it has not vi\"ELTP0923.png\"sited for years. But the gain was minor on Friday, and the new week opened with selling and a minor drop in prices.<\/p>\n

The only problem for SNGX<\/a> is that it has to rely on extraordinary events and threats. Some of its vaccines and anti-toxins may be stockpiled in anticipation, but this is also a hypothetical. While SNGX<\/a> is extraordinary in its qualities, it is still best to avoid investing, unless one can absorb the corrections that happen when a ticker hangs at a high peak.<\/p>\n","protected":false},"excerpt":{"rendered":"

Sologenix, Inc. (OTCBB:SNGX), a promising pharmaceutical ticker, is having a bit of trouble jumping over the $2 mark. For three days, buying has outspaced selling, but still there are competing forces working on the...<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[797,695,875],"class_list":["post-2622","post","type-post","status-publish","format-standard","hentry","category-news","tag-eltp","tag-nnvc","tag-sngx"],"_links":{"self":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts\/2622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/comments?post=2622"}],"version-history":[{"count":0,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/posts\/2622\/revisions"}],"wp:attachment":[{"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/media?parent=2622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/categories?post=2622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/articles.thehotpennystocks.com\/articles\/wp-json\/wp\/v2\/tags?post=2622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}